The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Evaluating the future role of VEGF inhibitors in pancreatic cancer
Salwan Al Mutar, MD, UT Southwestern Medical Center, Dallas, TX, comments on the potential role of VEGF inhibitors in managing pancreatic cancer. Nintedanib, an oral kinase inhibitor targeting VEGFR, PDGFR, and FGFR, was shown to have encouraging efficacy, and was well tolerated in a Phase Ib study (NCT02902484). It additionally had low rates of VEGF inhibitor-related adverse events such as hypertension. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
